NASDAQ:CBIO
Delisted
Catalyst Biosciences Stock News
$0.511
+0 (+0%)
At Close: Dec 14, 2023
Aptose Biosciences (APTO) Receives a Buy from JonesTrading - Markets
02:51pm, Friday, 12'th Jun 2020
In a report released today, Matthew Cross from JonesTrading maintained a Buy rating on Aptose Biosciences (APTO – Research Report),
Catalyst Biosciences Present at the Raymond James Human Health Innovation Conference
12:00pm, Friday, 12'th Jun 2020
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and systemic complement-mediated disorders. One of our key competitive
Catalyst Biosciences Completes MarzAA Pharmacokinetic & Pharmacodynamic Study
12:00pm, Wednesday, 10'th Jun 2020
The results support the use of SQ MarzAA to treat episodic bleeding. The company is on track to enroll the first patient in its Phase 3 registration trial evaluating the efficacy of SQ MarzAA to trea
Catalyst Biosciences Announces Oral and Poster Presentations at the World Federation of Hemophilia Virtual Summit 2020
12:00pm, Monday, 08'th Jun 2020
SOUTH SAN FRANCISCO, Calif., June 08, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced oral and poster presentations at the upcoming World Foundation of.
Catalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate Update
12:00pm, Monday, 11'th May 2020
MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback DalcA Phase 2b study completed, final data to be presented in.
Nanodevices for the brain could thwart formation of Alzheimer's plaques
01:08pm, Thursday, 30'th Apr 2020
Alzheimer's disease is the sixth leading cause of death in the United States, affecting one in 10 people over the age of 65. Scientists are engineering nanodevices to disrupt processes in the brain th
Athenex (ATNX) Receives a Buy from Oppenheimer
02:24am, Thursday, 30'th Apr 2020
In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX), with a price target of $23.00. The company's
Athenex (ATNX) Receives a Buy from Oppenheimer
02:24am, Thursday, 30'th Apr 2020
In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX – Research Report), with
Catalyst Biosciences Receives Patent in the European Union for Its Factor IX Portfolio
12:00pm, Tuesday, 28'th Apr 2020
SOUTH SAN FRANCISCO, Calif., April 28, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for.
Analysts Offer Insights on Healthcare Companies: Interpace Diagnostics Group (IDXG) and Principia Biopharma (PRNB)
02:22pm, Thursday, 23'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Interpace Diagnostics Group (IDXG) and Principia Biopharma
Oppenheimer Keeps Their Buy Rating on Athenex (ATNX)
09:57pm, Wednesday, 22'nd Apr 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX), with a price target of $23.00. The company's shares
Oppenheimer Keeps Their Buy Rating on Athenex (ATNX)
09:57pm, Wednesday, 22'nd Apr 2020
In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Athenex (ATNX – Research Report), with
Exact Sciences (EXAS) Gets a Buy Rating from Oppenheimer
12:31am, Wednesday, 22'nd Apr 2020
In a report released yesterday, Kevin DeGeeter from Oppenheimer assigned a Buy rating to Exact Sciences (EXAS), with a price target of $115.00. The
Exact Sciences (EXAS) Gets a Buy Rating from Oppenheimer
12:31am, Wednesday, 22'nd Apr 2020
In a report released yesterday,
Kevin DeGeeter
from Oppenheimer assigned a
Buy
rating to Exact Sciences (
EXAS
–
Research Report
), with a price target of
$115.00
. The company’s shares closed las
